Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022)
Enliven Therapeutics' (ELVN) quarterly Operating Leases came in at $2.0 million in Q1 2022, up 233.39% year-on-year from $590000.0 in Q1 2021, and up 384.48% quarter-over-quarter from $406000.0 in Q4 2021.
Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022) Analysis & Trends
Enliven Therapeutics has disclosed Operating Leases across 2 years of filings, most recently posting $2.0 million for Q1 2022.
- Operating Leases for Q1 2022 came in at $2.0 million, up 233.39% year-over-year; the trailing twelve-month figure through Mar 2022 was $2.0 million (up 233.39% YoY), and the FY2021 annual result was $406000.0, changed N/A from the prior year.
- Operating Leases came in at $2.0 million for Q1 2022 at Enliven Therapeutics, up from $406000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.0 million in Q1 2022 to a low of $406000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 406,000.00 |
| Sep 30, 2021 | 466,000.00 |
| Jun 30, 2021 | 528,000.00 |
| Mar 31, 2021 | 590,000.00 |